IMC Chicago’s Ascendis Pharma ASND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.54M Sell
24,300
-33,400
-58% -$8.46M ﹤0.01% 2137
2026
Q2
$15.4M Buy
57,700
+10,500
+22% +$2.45M ﹤0.01% 1247
2026
Q1
$10.8M Buy
47,200
+21,900
+87% +$4.91M ﹤0.01% 1207
2025
Q4
$5.39M Buy
25,300
+6,100
+32% +$1.26M ﹤0.01% 1683
2025
Q3
$3.82M Buy
+19,200
New +$3.58M ﹤0.01% 1762

Other funds holding ASND

IMC Chicago's ASND Position: Q1 2026 in Review

IMC Chicago sold out of Ascendis Pharma (ASND) in Q1 2026, closing a stake of 113,682 shares — an estimated $25.5M sold.

IMC Chicago first reported a position in ASND in Q4 2025 and held it in 1 quarter. The position peaked at $24.2M in Q4 2025. 278 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • IMC Chicago reported no remaining Ascendis Pharma position as of Q1 2026 after selling out during the quarter.
  • IMC Chicago sold 113,682 Ascendis Pharma shares in Q1 2026, an estimated $25.5M.
  • IMC Chicago first reported a position in Ascendis Pharma in Q4 2025 and held it in 1 quarter.
  • IMC Chicago's Ascendis Pharma position peaked at $24.2M in Q4 2025.
  • 278 funds tracked by Wall St. Rank held Ascendis Pharma as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.